Early Cognitive Interventions in Digital Format for Cancer Survivors (INCOTEM)
22 de julho de 2026 atualizado por: Biogipuzkoa Health Research Institute
Early Cognitive Interventions in Digital Format for Cancer Survivors - INCOTEM
The aim of this study is to evaluate the usability and effectiveness of two professionally supervised home-based cognitive training interventions as part of an early rehabilitation protocol for cancer-related cognitive impairment.
Participants will be randomized to one of the two intervention arms (computerized cognitive intervention or virtual reality cognitive intervention) or to the control group. Participants of the intervention groups will be assessed before and after the 10 weeks intervention or at equivalent time points for the control group. Comparisons between experimental and control participants, and between the participants in the two intervention arms, will be carried out to see which intervention is most effective and accepted.
Visão geral do estudo
Status
Status
Recrutamento
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
One of the adverse effects of cancer and its treatments is cognitive decline, which can affect up to 70% of patients throughout the course of their cancer journey. This decline leads to significant difficulties in resuming professional or social roles, among others, and to a reduced quality of life. Results from previous studies suggest that cognitive intervention can help restore affected functions. Within the framework of this project, two digital cognitive intervention platforms (BrainHQ and Enhance VR) have been selected because they offer advantages that make them viable, accessible and effective, such as: (1) being based on proven psychological paradigms; (2) providing a sufficient variety of exercises and difficulty levels; and (3) the ability to be administered at home. Virtual reality (VR) is demonstrating its potential in the healthcare field because it could help address the limitations of transfer and adherence in some cognitive intervention programs. In general, the virtual reality interventions are more ecological, so it is expected that the results will translate more effectively to the patient's daily activities. On the other hand, the greater immersion provides by VR increases motivation and, therefore, improves adherence to this type of interventions.
BrainHQ program consists of online exercises that target the following functions: attention, processing speed, memory, spatial orientation, interpersonal skills and intelligence. BrainHQ will be compared with the Enhace VR cognitive intervention, a library of 15 cognitive exercises developed in virtual reality to train and monitor specific cognitive functions (memory, attention, task flexibility, information processing, orientation, and problem-solving) and motor control.
The interventions will be implemented after the completion of cancer treatments (1-6 months post-chemotherapy) with the aim of promoting early detection of cognitive impairment and preventing it from becoming chronic over time. This will help patients resume their previous roles quickly and effectively.
The purpose of this randomized controlled trial is to test the usability and effectiveness of two digital cognitive interventions in cancer survivors in comparison with a control group.
The specific objectives are:
1) To compare the acceptance and adherence of the cognitive interventions. 2) To analyze the preliminary effectiveness of the interventions on patients' cognitive functioning and quality of life at two different time points: 2.A. Upon completion of the interventions 2.B. One year after completion of the interventions
Exploratory objective:
3) Conduct an exploratory cost study of the interventions compared to CAU (Care as Usual) The study is open to patients over 18 years of age with a cancer diagnosis (stages I-III) and subjective complaints of cognitive functioning related to the cancer diagnosis and/or cancer treatments, who completed chemotherapy treatment between 1 and 6 months prior.
After a first usability session at the hospital where the interventions dynamics are introduced, the interventions will be administered remotely under supervision. A psychologist will maintain weekly contact with the participants to check everything is going well.
Participants will be assessed before the intervention begins (T0) and again 10 weeks after (T1), once the intervention has finished. The follow-up assessment (T2) will take place one year after the intervention ends to examine the sustained effects of the intervention programs.
Improving the quality of life for cancer survivors is a global challenge that this project will help to address. The interventions of this project would help to reduce the time required to successfully resume work, family, and social responsibilities.
Tipo de estudo
Tipo de estudo
Intervencional
Inscrição (Estimado)
Inscrição
110
Estágio
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
Contato de estudo
- Nome: Dr. Ander Urruticoechea Ribate
- Número de telefone: +34943328000
- E-mail: ander.urruticoechearibate@osakidetza.eus
Estude backup de contato
- Nome: Dra. Mari Feli González
- Número de telefone: +34943328380
- E-mail: mariafeliciana.gonzalezperez@osakidetza.eus
Locais de estudo
-
-
Bizkaia
-
Bilbao, Bizkaia, Espanha, 48013
- Recrutamento
- Hospital Universitario Basurto
-
Contato:
- Dr. Ander Urruticoechea Ribate
- Número de telefone: +34943328000
- E-mail: ander.urruticoechearibate@osakidetza.eus
-
Contato:
- Dra. Mari Feli González
- Número de telefone: +34943328380
- E-mail: mariafeliciana.gonzalezperez@osakidetza.eus
-
Investigador principal:
- Covadonga Figaredo Berjano, Dr.
-
Galdakao, Bizkaia, Espanha, 48960
- Recrutamento
- Hospital Universitario Galdakao-Usansolo
-
Contato:
- Dr. Ander Urruticoechea Ribate
- Número de telefone: +34943328000
- E-mail: ander.urruticoechearibate@osakidetza.eus
-
Contato:
- Dra. Mari Feli González
- Número de telefone: +34943328380
- E-mail: mariafeliciana.gonzalezperez@osakidetza.eus
-
Investigador principal:
- Josefa Ferreiro Quintana, Dr.
-
-
Gipuzkoa
-
San Sebastián, Gipuzkoa, Espanha, 20014
- Recrutamento
- Hospital Universitario Donostia
-
Contato:
- Dr. Ander Urruticoechea Ribate
- Número de telefone: +34943328000
- E-mail: ander.urruticoechearibate@osakidetza.eus
-
Contato:
- Dra. Mari Feli González
- Número de telefone: +34943328380
- E-mail: mariafeliciana.gonzalezperez@osakidetza.eus
-
Investigador principal:
- Ander Urruticoechea Ribate, Dr.
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Patients over 18 years of age diagnosed with cancer (stage I-III)
- Subjective complaints of cognitive functioning related to the diagnosis of cancer and/or cancer treatments
- Between 1-6 months after completion of chemotherapy treatment
- To have Wi-Fi and a computer/tablet
- To sign the informed consent form
Exclusion Criteria:
- Previous history of cancer diagnosis
- Anticipated change in cancer treatment/general medical treatment during the intervention period
- Previous diagnosis of cognitive impairment
- Diagnosis of other neurological or psychiatric diseases
- Diagnosis of severe untreated depression
- History of episodes of vertigo, epilepsy or seizures
- Currently undergoing or having undergone any other type of intervention aimed at improving cognitive functioning (e.g., CRCI workshops)
- Severe visual or hearing difficulties that may affect the performance of the intervention exercises
- Inability to speak, understand, read, and write Spanish correctly
- Failure to sign the informed consent form
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
3
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Computerized cognitive training - BrainHQ
The arm will follow the cognitive training program BrainHQ.
|
Online exercises that target the following functions: attention, processing speed, memory, spatial orientation, interpersonal skills and intelligence. Participants will follow an online cognitive training with the BrainHQ program for 10 weeks. Patients will complete exercises that target attention, executive function, memory and processing speed. They will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week for 10 weeks, a total of 25 hours. Training progresses in an adaptive way, based on the progression of the participant. |
|
Experimental: Virtual Reality cognitive training - Enhance VR
The arm will follow the cognitive training program Enhance VR.
|
A library of 15 cognitive exercises developed in virtual reality to train and monitor specific cognitive functions (memory, attention, task flexibility, information processing, orientation, and problem-solving) and motor control. Participants will follow a virtual reality cognitive training with the Enhance VR program for 10 weeks. Patients will complete exercises that target attention, executive function, memory and processing speed. Participants will be asked to train approximately 30 minutes per Enhance VR session, 4 times per week for 10 weeks, a total of 20 hours. Training progresses in an adaptive way, based on the progression of the participant. |
|
Sem intervenção: Control Group
The arm will receive usual care with no cognitive intervention
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Perceived Cognitive Function
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Functional Assessment of Cancer Therapy-Cognition, FACT-Cog v3 Self-report questionnaire for cancer patients with cognitive problems consisting of 37 items divided in 4 subscales: Perceived Cognitive Impairment (PCI), Perceived Cognitive Abilities (PCA), Comments From Others (OTH), and Impact on Quality of Life (QoL). The items asked for the past 7 days and are rated on a 5-point Likert scale. Higher scores are indicative of a better cognitive function and QoL. |
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence
Prazo: Throughout the 10-week intervention
|
Sufficient adherence is defined by completing at least 70% of the required exercise levels
|
Throughout the 10-week intervention
|
|
Change in Montreal Cognitive Assessment (MoCA) score
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention
|
MoCA: screening tool aiming to detect cognitive impairment.
Total score ranges from 0 to 30, with higher scores indicating better cognitive function.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention
|
|
Change in Hopkins Verbal Learning Test-Revised (HVLT-R) score
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention
|
The HVLT-R assesses learning and immediate and delayed verbal memory.
The number of words remembered ranges from 0 to 36 (immediate memory) and from 0 to 12 (delayed memory).
Higher scores, words remembered, are indicative of better memory.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention
|
|
Change in Trail Making Test (TMT) completion time
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention
|
Consists of two parts, to connect numbers in ascending order and to alternate connecting numbers and letters in ascending order.
The final score is the time taken to complete the task.
The longer it takes, the poorer the cognitive performance.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention
|
|
Change in Verbal Fluency score
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Consists of phonological fluency (P-M-R) and semantic fluency (animals, fruits and vegetables).
Each word correctly given in each category counts as a point.
Higher scores mean better verbal fluency.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in Digit Span (WAIS-IV) score
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Measures attention (Digits Forward) and working memory (Digits Backward).
The participant must repeat a number sequence.
Higher scores, total number sequences correctly repeated, indicate better performance.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in Symbol Search (WAIS-IV) score
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Measures processing speed.
Higher scores, number of correctly correct answers, indicate better processing speed.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in CANTAB Reaction Time (RTI)
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Cognitive test (higher score indicating better outcome).
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in CANTAB Rapid Visual Information Processin (RVP)
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Cognitive test (higher score indicating better outcome)
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in CANTAB Delayed Matching to Sample (DMS)
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Cognitive test (higher score indicating better outcome)
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in CANTAB Paired Associated Matching (PAL)
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Cognitive test (higher score indicating better outcome)
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in CANTAB Spatial Working Memory (SWM)
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Cognitive test (higher score indicating better outcome)
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in CANTAB One Touch Stockings of Cambridge (OTS)
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Cognitive test (higher score indicating better outcome)
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in Hopkins Verbal Learning Test-Revised (HVLT-R) score
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Assesses learning and immediate and delayed verbal memory.
The number of words remembered ranges from 0 to 36 (immediate memory) and from 0 to 12 (delayed memory).
Higher scores, words remembered, are indicative of better memory.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in Fatigue
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
EORTC - QCL - FA-12, is a 12-item Likert scale.
It evaluates the physical, emotional, and cognitive aspects of fatigue and the interference of it with daily activities and social life in the last 7 days.
The items range from 1 to 4 with higher values representing higher symptomatology.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in Sleep Disturbance
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Insomnia Severity Index - ISI.
It consists of 7 questions asking for difficulties of falling asleep, staying asleep, and problems with waking up too early, current sleep patterns and the effects of sleep on quality of life.
Higher scores indicate more sleep problems.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in Anxiety and Depression symptoms
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Hospital Anxiety and Depression Scale (HADS).
It is used to assess anxiety and depression in a hospital setting.
This scale consisted of 14 questions, where half of the questions are related to anxiety and the other half to depression.
Each item ranges from 0 to 3. Higher scores indicate the presence of anxiety and/or depression.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in overall Quality of Life
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
EORTC QLQ-C-30.
This assessment consisted of 30 questions addressing several aspects of quality of life in cancer patients (Functioning scales: physical, emotional, social, cognitive and role; Symptoms scales: fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea symptoms, plus financial difficulties and global health status / quality of life scale).
For each scale, scores range from 0 to 100, with higher scores indicating good functioning in the functioning scales and more symptoms burden in the symptoms scales.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in Work Ability Index (WAI)
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
The first two items of the WAI scale rated the current work ability on a Likert scale from 1 to 10 and the current work ability with respect to the physical and the mental demands of the work.
On both items higher scores reflect better work ability.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Change in adherence medication
Prazo: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
Morisky Medication Adherence Scale (MMAS-8) (MMAS-8).
The scale consists of 8 items.
Response choices are "yes" or "no" for items 1-7 and Item 8 has a five-point Likert response scale.
Total scores on the MMAS-8 range from 0 to 8, with higher scores meaning higher adherence.
|
Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
|
|
Patient Satisfaction
Prazo: Thoughout the 10-week intervention.
|
Net Promoter Score (NPS), assesses satisfaction with a specific product or service by asking how likely that person is to recommend it to someone else on a scale of 0 (not at all likely) to 10 (extremely likely).
The final score is calculated by dividing the percentage of promoters (those who score 9-10) by the percentage of detractors (those who score 0-6).
The NPS range varies between -100 and +100, with a positive score being considered acceptable and the higher the score, the more acceptable it is considered to be.
Client Satisfaction Questionnaire (CSQ-8).
Likert-based 8-item questionnaire rating overall satisfaction and acceptability.
The 8 items are scored on a 4-point scale (total range from 8-32) with higher scores indicating greater acceptability and satisfaction.
|
Thoughout the 10-week intervention.
|
|
Subjective experience with the exercises
Prazo: At the usability session.
|
Game Experience Questionnaire (GEQ).
The Core Module consists of 33 items which assess game experience on seven components: Immersion, Flow, Competence, Positive and Negative Affect, Tension, and Challenge.
Each item is rated from 0 (Not at all) to 4 (Extremely).
High score in a concrete dimension means intense experience on that dimension.
|
At the usability session.
|
|
Usability
Prazo: Thoughout the 10-week intervention.
|
System Usability Scale (SUS), is a 10-item self-report measure designed for usability assessment.
Items are rated on a 5- 8 point Likert scale (1 = strongly disagree, 5 = strongly agree).
Total SUS scores have a range of 0 to 100, being higher scores in the SUS indicative of greater usability.
|
Thoughout the 10-week intervention.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, Boyle F, Price MA, Vardy JL. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol. 2017 Jan 10;35(2):217-225. doi: 10.1200/JCO.2016.67.8201. Epub 2016 Oct 28.
- Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012 Nov;38(7):926-34. doi: 10.1016/j.ctrv.2012.05.002. Epub 2012 Jun 2.
- Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012 Apr 1;30(10):1080-6. doi: 10.1200/JCO.2011.37.0189. Epub 2012 Feb 27.
- Lange M, Joly F. How to Identify and Manage Cognitive Dysfunction After Breast Cancer Treatment. J Oncol Pract. 2017 Dec;13(12):784-790. doi: 10.1200/JOP.2017.026286.
- Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014 Feb;26(1):102-13. doi: 10.3109/09540261.2013.864260.
- Zeng Y, Guan Q, Su Y, Huang Q, Zhao J, Wu M, Guo Q, Lyu Q, Zhuang Y, Cheng AS. A self-administered immersive virtual reality tool for assessing cognitive impairment in patients with cancer. Asia Pac J Oncol Nurs. 2023 Feb 28;10(3):100205. doi: 10.1016/j.apjon.2023.100205. eCollection 2023 Mar.
- Wu LM, Amidi A, Tanenbaum ML, Winkel G, Gordon WA, Hall SJ, Bovbjerg K, Diefenbach MA. Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer. 2018 Jun;26(6):1917-1926. doi: 10.1007/s00520-017-4026-8. Epub 2017 Dec 27.
- Von Ah D, Crouch A, Storey S. Acceptability of computerized cognitive training and global cognitive stimulating-based games delivered remotely: Results from a randomized controlled trial to address cancer and cancer-related cognitive impairment in breast cancer survivors. Cancer Med. 2023 Jun;12(11):12717-12727. doi: 10.1002/cam4.5904. Epub 2023 Apr 11.
- Von Ah D, McDonald BC, Crouch AD, Ofner S, Perkins S, Storey S, Considine R, Unverzagt F. Randomized double-masked controlled trial of cognitive training in breast cancer survivors: a preliminary study. Support Care Cancer. 2022 Sep;30(9):7457-7467. doi: 10.1007/s00520-022-07182-4. Epub 2022 Jun 1.
- Serweta-Pawlik A, Lachowicz M, Zurek A, Rosen B, Zurek G. Evaluating the Effectiveness of Visuospatial Memory Stimulation Using Virtual Reality in Head and Neck Cancer Patients-Pilot Study. Cancers (Basel). 2023 Mar 7;15(6):1639. doi: 10.3390/cancers15061639.
- Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016 Feb 20;34(6):611-35. doi: 10.1200/JCO.2015.64.3809. Epub 2015 Dec 7.
- Mayo SJ, Rourke SB, Atenafu EG, Vitorino R, Chen C, Kuruvilla J. Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study. Pilot Feasibility Stud. 2021 Jan 30;7(1):36. doi: 10.1186/s40814-021-00778-3.
- Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, Joly F. Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey. Cancer Med. 2019 May;8(5):2654-2663. doi: 10.1002/cam4.2069. Epub 2019 Mar 18.
- Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancre V, Lange M, Castel H. Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage. 2015 Dec;50(6):830-41. doi: 10.1016/j.jpainsymman.2015.06.019. Epub 2015 Sep 5.
- Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E. Effectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled trial. Trials. 2022 Sep 30;23(1):819. doi: 10.1186/s13063-022-06731-w.
- Brugada-Ramentol V, Bozorgzadeh A, Jalali H. Enhance VR: A Multisensory Approach to Cognitive Training and Monitoring. Front Digit Health. 2022 Jun 3;4:916052. doi: 10.3389/fdgth.2022.916052. eCollection 2022.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
8 de junho de 2026
Conclusão Primária (Estimado)
Conclusão Primária
30 de abril de 2028
Conclusão do estudo (Estimado)
Conclusão do estudo
30 de abril de 2028
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
5 de junho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
22 de julho de 2026
Primeira postagem (Real)
Primeira postagem
28 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
28 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
22 de julho de 2026
Última verificação
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- INCOTEM
- BIO24/CA/020/BG (Outro identificador: Fundación Vasca de Innovación e Investigación Sanitarias)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .